| _version_ | 1866901891669032960 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | Multiple proprietary treatments are available for NSCLC, targeting specific genetic mutations with varying recent licensing dates. These treatments include selpercatinib, pembrolizumab, osimertinib, alectinib, anlotinib, and durvalumab, among others. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17823410 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | What proprietary (non-generic) treatments are available for NSCLC, and when were they licensed? Tripdatabase proprietary non generic treatments available nsclc when licensed Multiple proprietary treatments are available for NSCLC, targeting specific genetic mutations with varying recent licensing dates. These treatments include selpercatinib, pembrolizumab, osimertinib, alectinib, anlotinib, and durvalumab, among others. |
| title | What proprietary (non-generic) treatments are available for NSCLC, and when were they licensed? |
| topic | proprietary non generic treatments available nsclc when licensed |
| url | https://doi.org/10.5281/zenodo.17823410 |